Investor Relations

Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patients’ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a wholly-owned pipeline of three rare disease endocrinology product candidates in clinical development.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.63 (0.94%)
Data as of 05/18/18 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $66.29 with a 52 week high of $70.50 and a 52 week low of $21.95.
Recent NewsMore >>
Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
Upcoming EventsMore >>
Q1 2018 Ascendis Pharma Earnings Conference Call
Wednesday, May 30, 2018 4:30 p.m. ET
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.